Treatment Outcomes Comparison

This note sets the two treatment tracks in this vault side by side for toddlers aged 1–4 with Atopic Dermatitis. Track A is home, herbal and “natural” care, covered in the hub Herbal and Home Remedies for Eczema. Track B is doctor-prescribed care: daily Emollient Therapy, Topical Corticosteroids (TCS) for flares, Weekend Therapy to prevent flares, Topical Calcineurin Inhibitors (TCIs) as steroid-sparing options, and Dupilumab for severe disease. The two tracks overlap. Plain moisturising is the base of Track B, and the best-supported Track A products (Colloidal Oatmeal, Sunflower Seed Oil, Coconut Oil) work, when they work, as emollients. The real difference is in anti-inflammatory treatment. Track B has Cochrane-level evidence that TCS clear flares and prevent new ones. Track A has nothing comparable. Its best-studied oral remedies (Evening Primrose Oil, Probiotics, Chinese Herbal Medicine) have been tested and found not to work. Every figure below comes from the linked notes and their sources. Few trials enrolled only 1–4-year-olds, so most numbers are from mixed child or child-and-adult populations.

Treatment Outcomes Comparison [relates] Herbal and Home Remedies for Eczema Treatment Outcomes Comparison [relates] Emollient Therapy Treatment Outcomes Comparison [relates] Topical Corticosteroids Emollient Therapy [part-of] Herbal and Home Remedies for Eczema

Summary table

Cochrane [supports] Topical Corticosteroids Cochrane [contradicts] Evening Primrose Oil Cochrane [contradicts] Probiotics Weekend Therapy [prevents] Atopic Dermatitis

Effectiveness and time to improvement

Track B’s core has strong evidence. The 2017 Cochrane review of moisturisers (van Zuuren; 77 RCTs, 6,603 people) found high-certainty reductions in severity and fewer flares. Moisturiser plus active treatment beat active treatment alone. The BEE Trial (550 children, median age 4) found no difference between lotion, cream, gel and ointment, so the cheapest product the child will accept is a reasonable choice. For flares, the 2022 Cochrane review of TCS (Lax; 104 RCTs) showed a clear potency gradient, and once-daily potent TCS was probably as effective as twice-daily. NICE CG57 treats 7–14 days as the window: if mild or moderate TCS have not controlled a flare in that time, a child over 12 months may step up to a potent TCS for up to 14 days, never on the face. TCIs are second-line partly because they act more slowly than TCS (PCDS, via Topical Calcineurin Inhibitors). Track A has a few positive small trials, all short and none toddler-specific. Topical Breast Milk matched hydrocortisone 1% at 21 days in one infant RCT, but a split-body pilot in children aged 4–32 months found no effect. Coconut oil beat mineral oil over 8 weeks. Kamillosan Chamomile cream did no better than its vehicle over 2 weeks. Manuka Honey was tested for 7 days in 14 adults. No study reports how quickly a home remedy improves a toddler’s eczema compared with TCS.

NICE CG57 [defines] Topical Corticosteroids BEE Trial [supports] Emollient Therapy Breast Milk [relates] Hydrocortisone Coconut Oil [treats] Atopic Dermatitis

Conflict: [Evangelista et al., Int J Dermatol 2014] found virgin coconut oil superior to mineral oil in 117 children (SCORAD −68% vs −38%). [Karagounis et al., Pediatr Dermatol 2019] and [AAP, n.d.] say coconut oil’s role “remains to be determined”. Carried over from Herbal and Home Remedies for Eczema. Unresolved — add to open_questions.

Flare prevention and side effects

Flare prevention is Track B’s clearest advantage. In Cochrane 2022 (7 trials, 1,149 people), twice-weekly TCS on usual flare sites after control cut flares from about 576 to 248 per 1,000 (NNT ≈3, moderate certainty). Schmitt 2011 pooled vehicle-controlled RCTs: proactive fluticasone gave RR 0.46 and proactive Tacrolimus RR 0.78. By indirect comparison that is roughly 2 patients treated with fluticasone versus 4 with tacrolimus to prevent one flare (Williams editorial). Neither review enrolled many toddlers, and tacrolimus 0.03% is licensed only from age 2. No Track A product has been tested as maintenance. On harms, Track B’s risks are well mapped and depend on potency and duration. The prevention trials found no Skin Atrophy in 1,050 participants. The Axon 2021 umbrella review found reversible biochemical HPA Axis Suppression in 3.8% of children in uncontrolled studies, with no growth effect. Track A’s harms are less studied but sometimes serious: Olive Oil disrupting the barrier, Essential Oils causing poisoning, peanut-oil skin creams linked to peanut allergy (ALSPAC, OR 6.8), and Adulterated Herbal Creams containing clobetasol, the strongest prescription steroid. A family avoiding TCS can end up applying an unlabelled, very potent one. In Birmingham, 20 of 24 “herbal” creams used by children contained steroids (Ramsay 2003, via Steroid Phobia).

Weekend Therapy [part-of] Topical Corticosteroids Topical Calcineurin Inhibitors [part-of] Weekend Therapy Adulterated Herbal Creams [part-of] Topical Corticosteroids Olive Oil [worsens] Atopic Dermatitis

Conflict: [Axon et al., BMJ Open 2021] and [Cochrane, Lax 2022] found no evidence of harm from weekend TCS. [Ahuja & Lio, Pediatric Dermatology 2025] report paediatric Topical Steroid Withdrawal cases with use patterns down to twice weekly. Carried over from Weekend Therapy. Unresolved — add to open_questions.

"Natural" creams with undeclared steroids

A “herbal” or “steroid-free” cream that clears a toddler’s eczema unusually fast may contain a potent steroid such as clobetasol (MHRA 2018: Yiganerjing, Zudaifu). Used on the face or large areas without supervision, it carries more steroid risk than the mild prescribed hydrocortisone the family was trying to avoid. In the UK, check for a PL or THR number. See Adulterated Herbal Creams.

Essential oils, fragrance and nut-based oils on broken skin

Essential and fragranced oils irritate and sensitise eczematous skin, and swallowed tea tree oil has poisoned children (NCCIH). Peanut-oil skin preparations were linked to peanut allergy in ALSPAC (OR 6.8). Keep both off a toddler’s eczema.

Unsupervised food elimination diets

Removing dairy, egg or wheat without allergy testing does not treat eczema. It risks calcium, vitamin D, iodine, protein and energy deficits, and can create immediate-type allergy when the food is reintroduced (Kohl 2026; Dobrijević 2026). See Elimination Diets.

Cost and adherence

How much each track costs depends on the health system. In the UK, prescriptions are free for under-16s. Cost then falls on the NHS, and PrescQIPP guidance steers prescribers to low-cost products: emollients under £1.15 per 100 g, and hydrocortisone 1% rather than 2.5%, which costs 18–58 times more per gram. A 30 g tube of Protopic 0.03% has an NHS indicative price of £23.33. In 1995–96, AD in Nottingham children aged 1–5 cost £79.59 per child per year in total, and 36% of that fell on families, including OTC products and homoeopath visits (Emerson 2001). In the US, families pay much more out of pocket. Caregivers of children reported a median of $860 a year (Chovatiya 2023). Almost all of them paid for moisturisers themselves, which makes Track B’s foundation an out-of-pocket cost much like Track A products. Details are in Cost of Eczema Care. Adherence is Track B’s weak point. Non-adherence was 49.4% in steroid-phobic groups against 14.1% in others. The resulting under-treatment produces poor results, which “confirm” parents’ fears and push some families toward Track A (Steroid Phobia). Track A has no adherence studies. In the Leicester clinic, 54% of CAM users had turned to it because conventional treatment “wasn’t working” and 17% out of fear of steroids. Only 35% saw improvement, and 56% would not recommend CAM (Johnston 2003).

Steroid Phobia [causes] Herbal and Home Remedies for Eczema Steroid Phobia [opposes] Topical Corticosteroids Cost of Eczema Care [relates] Treatment Outcomes Comparison PrescQIPP [regulates] Emollient Therapy

Long-term prognosis

Neither track has been shown to change how eczema turns out in the long run. In the German Multicenter Allergy Study, 43.2% of children with eczema in their first 2 years were in complete remission by age 3, 38.3% had an intermittent course, and 18.7% had symptoms every year to age 7. Severity, early onset and allergic sensitisation predicted persistence. Eczema Prognosis found no study showing that any treatment changes whether a child outgrows eczema, or that early aggressive control prevents the Atopic March. Emollients from birth did not prevent eczema in the BEEP trial. So the choice of track determines how the toddler’s skin, sleep and quality of life fare during the active years, not whether the eczema eventually goes. On that measure, Track B has the evidence. There is also no evidence that TCS worsen the long-term course (Moret 2013; Illi 2004, via Topical Corticosteroids).

Eczema Prognosis [relates] Treatment Outcomes Comparison Multicenter Allergy Study [supports] Eczema Prognosis Atopic March [relates] Eczema Prognosis Sleep Disturbance in Eczema [relates] Atopic Dermatitis

Conflict: [Kim et al., JAAD 2016] says 80% of childhood AD has remitted 8 years after diagnosis. [Margolis et al., JAMA Dermatol 2014, PEER] says over 80% of children aged 2–26 still had symptoms or were using treatment. Carried over from Eczema Prognosis. Unresolved — add to open_questions.

Connections

• Herbal and Home Remedies for Eczema — Track A hub, source: Johnston 2003; Cochrane 2013/2018
• Emollient Therapy — foundation shared by both tracks, source: Cochrane 2017; BEE 2022
• Topical Corticosteroids — Track B flare treatment, potency gradient, source: Cochrane Lax 2022
• Hydrocortisone — mild TCS, low-cost 1% form, source: PrescQIPP 307
• Weekend Therapy — proactive TCS/TCI, NNT ≈3, source: Cochrane 2022; Schmitt 2011
• Topical Calcineurin Inhibitors — slower-acting, steroid-free, £23.33/30 g, source: PCDS; NHS dm+d
• Tacrolimus — proactive RR 0.78, source: Schmitt 2011
• Dupilumab — 28% vs 4% clear at 16 weeks, high cost, source: LIBERTY AD PRESCHOOL; BNF 2018
• Cost of Eczema Care — family and NHS cost data, source: Chovatiya 2023; Emerson 2001
• Eczema Prognosis — no treatment changes natural course, source: Illi 2004
• Steroid Phobia — main driver of non-adherence and CAM uptake, source: 2017 review; Johnston 2003
• Adulterated Herbal Creams — hidden potent steroids in Track A products, source: MHRA 2018
• Colloidal Oatmeal — best-supported Track A product, source: Lisante 2017
• Coconut Oil — one positive paediatric RCT, contested, source: Evangelista 2014
• Evening Primrose Oil — strong evidence of no benefit, source: Cochrane 2013
• Probiotics — little or no benefit, source: Cochrane 2018
• Chinese Herbal Medicine — no conclusive benefit, source: Cochrane 2013
• Breast Milk — ≈ hydrocortisone at 21 days in one RCT, source: Kasrae 2015
• Olive Oil — barrier damage, source: Danby 2013
• Essential Oils — irritant and poisoning risk, source: NCCIH
• Elimination Diets — nutritional and new-allergy hazards, source: Kohl 2026
• Skin Atrophy — none in prevention trials, source: Cochrane 2022
• HPA Axis Suppression — 3.8% of children, reversible, source: Axon 2021
• Topical Steroid Withdrawal — disputed risk at low-frequency use, source: Ahuja & Lio 2025
• Multicenter Allergy Study — 43.2% remission by age 3, source: Illi 2004
• Atopic March — not shown to be prevented by any treatment, source: Medicina 2024
• PrescQIPP — NHS cost-effective prescribing guidance, source: PrescQIPP 307
• Cochrane — reviews underpinning both tracks, source: CD012119; CD013356